Ken Griffin Apellis Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$28.84 - $41.15 $2.15 Million - $3.06 Million	-74,400 Reduced 34.08%	143,900 $4.15 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $3.08 Million - $4.83 Million	80,900 Added 58.88%	218,300 $8.37 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $14.3 Million - $18.7 Million	-257,500 Reduced 65.21%	137,400 $8.08 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $10.6 Million - $18.5 Million	-285,000 Reduced 41.92%	394,900 $23.6 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $13 Million - $49 Million	549,300 Added 420.6%	679,900 $25.9 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $6.74 Million - $8.2 Million	-87,900 Reduced 40.23%	130,600 $11.9 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $3.29 Million - $4.73 Million	-70,700 Reduced 24.45%	218,500 $14.4 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $3.67 Million - $5.18 Million	84,900 Added 41.56%	289,200 $15 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $980,244 - $1.53 Million	21,900 Added 12.01%	204,300 $14 Million

309

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.75B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.